Onesource Specialty Pharma Ltd
NSE:ONESOURCE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L E Lundbergforetagen AB (publ)
STO:LUND B
|
SE |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (112.8), the stock would be worth ₹1 136.94 (26% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 153.2 | ₹1 543.5 |
0%
|
| 3-Year Average | 112.8 | ₹1 136.94 |
-26%
|
| 5-Year Average | 112.8 | ₹1 136.94 |
-26%
|
| Industry Average | 29.1 | ₹293.09 |
-81%
|
| Country Average | 23.3 | ₹234.46 |
-85%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
₹153.1B
|
/ |
Jan 2026
₹1.2B
|
= |
|
|
₹153.1B
|
/ |
Mar 2026
₹241.4m
|
= |
|
|
₹153.1B
|
/ |
Mar 2027
₹5.5B
|
= |
|
|
₹153.1B
|
/ |
Mar 2028
₹10B
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
O
|
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
|
176.6B INR | 153.2 | 878.7 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 357.2 | 4 272.3 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
198.1B USD | 27.4 | 29.6 | |
| US |
|
Danaher Corp
NYSE:DHR
|
137.7B USD | 28.2 | 38.1 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.3B CHF | 27.8 | -130.4 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
296.6B CNY | 16.1 | 15.5 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.5B USD | 23 | 26.5 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.2B USD | 41.1 | 50.6 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.9B USD | 18.3 | 22.1 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.3B USD | 25.5 | 31 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 15.7 |
| Median | 23.3 |
| 70th Percentile | 34.7 |
| Max | 48 145.1 |
Other Multiples
Onesource Specialty Pharma Ltd
Glance View
Onesource Specialty Pharma Ltd is a IN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Bangalore, Karnataka and currently employs 525 full-time employees. The company went IPO on 2025-01-24. OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. The company operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The firm specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. The company supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The firm caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.
